electroCore (ECOR) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
16 Dec, 2025Management team and governance
CEO is Daniel S. Goldberger; CFO is Joshua S. Lev; F. Peter Cuneo serves as Chairman of the Board.
Board includes Thomas J. Errico, M.D., John P. Gandolfo, Julie A. Goldstein, Thomas M. Patton, Charles S. Theofilos, M.D., and Patricia Wilber.
Directors and officers have entered into indemnification agreements providing broad protection against liabilities, except for willful misconduct.
Certificate of incorporation and bylaws limit director liability and provide for indemnification to the fullest extent permitted by Delaware law.
Directors' and officers' liability insurance is in place to cover defense, settlement, or judgment costs in certain circumstances.
Risk factors and disclosures
Indemnification for liabilities under the Securities Act may be unenforceable as it is against public policy according to the SEC.
Offering details and pricing
Registration statement covers up to $100,000,000 of securities, including $46,248,961 of unsold securities from a prior registration.
Securities may be offered from time to time or at one time after effectiveness, depending on market conditions.
Filing fees previously paid for unsold securities will be applied to this offering.
All expenses related to issuance and distribution will be borne by the company.
Latest events from electroCore
- Bioelectronic medicine leader with rapid growth, FDA-cleared devices, and expanding wellness portfolio.ECOR
Corporate presentation25 Mar 2026 - 2025 revenue up 27% to $32M; 2026 revenue guided +30% amid leadership changes.ECOR
Q4 202520 Mar 2026 - Q2 sales up 73%, net loss narrowed, and strong VA/DoD and wellness product growth.ECOR
Q2 20242 Feb 2026 - Rapid growth, high margins, and expanding clinical pipeline position for broader market access.ECOR
LD Micro Main Event XVI18 Jan 2026 - Q3 revenue up 45% year-over-year, net loss narrows, and cash position strengthens.ECOR
Q3 202414 Jan 2026 - 2024 revenue up 57% to $25.2M, net loss narrowed, and gross margin reached 85%.ECOR
Q4 202419 Dec 2025 - Shelf registration allows up to $100M in offerings, including a $20M ATM with H.C. Wainwright & Co.ECOR
Registration Filing16 Dec 2025 - Shelf and ATM offerings target $100M for growth amid strong government sales and ongoing risks.ECOR
Registration Filing16 Dec 2025 - Registering 762,508 shares for resale after private placements and a $12M loan for growth.ECOR
Registration Filing16 Dec 2025